Acne Scars for Acne

Phase-Based Progress Estimates
UnionDerm, New York, NY
Acne+2 More
Sofwave - Device
All Sexes
What conditions do you have?

Study Summary

Open-label, non-randomized, prospective, multi-center, self-controlled clinical study with masked evaluation.

Eligible Conditions

  • Acne
  • Acne Scars - Mixed Atrophic and Hypertrophic

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 1 year

1 year
Rate of improvement of acne scars appearance, as assessed by independent masked evaluators at 3 months post last treatment session.

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Acne Scars
1 of 1
Experimental Treatment

60 Total Participants · 1 Treatment Group

Primary Treatment: Acne Scars · No Placebo Group · N/A

Acne Scars
Experimental Group · 1 Intervention: Sofwave · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year
Closest Location: UnionDerm · New York, NY
Photo of New York  1Photo of New York  2Photo of New York  3
N/AFirst Recorded Clinical Trial
0 TrialsResearching Acne
0 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are able and willing to comply with all visits, treatments and evaluations schedules and requirements.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.